Price
$1.08
Change
-$0.01 (-0.92%)
Updated
Jun 2, 6:59 PM EST
GET INTRADAY SIGNALS
62 days until earnings call
Price
$4.38
Change
-$0.09 (-2.01%)
Updated
Jun 2, 10:56 AM EST
GET INTRADAY SIGNALS
68 days until earnings call

Compare predictions ADAP vs MNKD

Header iconADAP vs MNKD Comparison
Open Charts ADAP vs MNKDBanner chart's image
Adaptimmune Therapeutics
Price$1.08
Change-$0.01 (-0.92%)
Volume$654K
CapitalizationN/A
GET INTRADAY SIGNALS
MannKind
Price$4.38
Change-$0.09 (-2.01%)
Volume$1.27K
CapitalizationN/A
GET INTRADAY SIGNALS
View a ticker or compare two or three
ADAP vs MNKD Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ADAP vs. MNKD commentary
Jun 02, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and MNKD is a StrongBuy.

COMPARISON
Comparison
Jun 02, 2023
Stock price -- (ADAP: $1.09 vs. MNKD: $4.48)
Brand notoriety: ADAP and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 109% vs. MNKD: 63%
Market capitalization -- ADAP: $180.62M vs. MNKD: $1.18B
ADAP [@Biotechnology] is valued at $180.62M. MNKD’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $360.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 3 green FA rating(s).

  • ADAP’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 3 green, 2 red.
According to our system of comparison, MNKD is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 6 bearish.
  • MNKD’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а -6.84% price change this week, while MNKD (@Biotechnology) price change was -1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.87%. For the same industry, the average monthly price growth was +46.28%, and the average quarterly price growth was +54.61%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 03, 2023.

MNKD is expected to report earnings on Aug 09, 2023.

Industries' Descriptions

@Biotechnology (+4.87% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ADAP with price predictions.
OPEN
A.I.dvisor published
a Summary for MNKD with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MNKD($1.18B) has a higher market cap than ADAP($181M). MNKD YTD gains are higher at: -14.991 vs. ADAP (-26.027). MNKD has higher annual earnings (EBITDA): -36.72M vs. ADAP (-102M). ADAP (166M) and MNKD (166M) have equal amount of cash in the bank . ADAP has less debt than MNKD: ADAP (22.8M) vs MNKD (383M). MNKD has higher revenues than ADAP: MNKD (128M) vs ADAP (71.2M).
ADAPMNKDADAP / MNKD
Capitalization181M1.18B15%
EBITDA-102M-36.72M278%
Gain YTD-26.027-14.991174%
P/E RatioN/AN/A-
Revenue71.2M128M56%
Total Cash166M166M100%
Total Debt22.8M383M6%
FUNDAMENTALS RATINGS
ADAP vs MNKD: Fundamental Ratings
ADAP
MNKD
OUTLOOK RATING
1..100
5576
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
5
Undervalued
PROFIT vs RISK RATING
1..100
10032
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
8943
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (5) in the Biotechnology industry is in the same range as ADAP (33). This means that MNKD’s stock grew similarly to ADAP’s over the last 12 months.

MNKD's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for ADAP (100). This means that MNKD’s stock grew significantly faster than ADAP’s over the last 12 months.

ADAP's SMR Rating (98) in the Biotechnology industry is in the same range as MNKD (100). This means that ADAP’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for ADAP (89). This means that MNKD’s stock grew somewhat faster than ADAP’s over the last 12 months.

MNKD's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for ADAP (100). This means that MNKD’s stock grew significantly faster than ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPMNKD
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 19 days ago
83%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANORX14.800.15
+1.02%
American Century Small Cap Growth R
MADVX18.380.10
+0.55%
BlackRock Equity Dividend Instl
GTSGX12.990.03
+0.23%
Madison Mid Cap Y
HDCAX7.55N/A
N/A
Rational Equity Armor Fund A
SECAX9.67N/A
N/A
SEI Small Cap II A (SIIT)

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with ADPT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-0.92%
ADPT - ADAP
44%
Loosely correlated
+5.82%
MNKD - ADAP
38%
Loosely correlated
-0.45%
ORMP - ADAP
36%
Loosely correlated
-2.90%
CYTK - ADAP
36%
Loosely correlated
+1.77%
AGIO - ADAP
36%
Loosely correlated
+1.32%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VXRT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VXRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-3.45%
VXRT - MNKD
59%
Loosely correlated
+2.46%
AGIO - MNKD
57%
Loosely correlated
+1.70%
EDIT - MNKD
57%
Loosely correlated
+4.03%
FOLD - MNKD
54%
Loosely correlated
+1.15%
INO - MNKD
53%
Loosely correlated
-4.44%
More